FOX8 Cleveland

Alpha Fusion, Inc. and Curadh MTR, Inc. to Enter into Strategic Partnership to Advance Global Development of Astatine-211 Based Radiopharmaceuticals

TOKYO, June 30, 2025 /PRNewswire/ -- Alpha Fusion, Inc. ("Alpha Fusion") and Curadh MTR Inc. ("Curadh") announced plans to enter a strategic partnership, including a Joint Venture to broadly advance ...
Seeking Alpha

Fusion Pharmaceuticals Announces First Patient Dosed in Phase 1 Study of FPI-2059, a Targeted Alpha Therapy (TAT) for the Treatment of Solid Tumors Expressing NTSR1

HAMILTON, ON and BOSTON, March 20, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as ...
Seeking Alpha

Fusion Pharmaceuticals and BWXT Medical Announce Actinium-225 Partnership to Scale Supply for Developing Targeted Alpha Therapies

HAMILTON, ON, Jan. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (BWXT), today announced that the companies have entered ...
abc27

Alpha Fusion and Kobe City Medical Center General Hospital Establish At-211 Investigational Drug Supply System

TOKYO, Oct. 8, 2025 /PRNewswire/ -- Alpha Fusion Inc. (Alpha Fusion) is proud to announce a joint initiative with the Kobe City Medical Center General Hospital (KCGH) to establish a domestic supply ...
ksn.com

Curadh and Alpha Fusion Advance Astatine-211 Radiopharmaceuticals Partnership

CHESTER SPRINGS, Pa., July 23, 2025 /PRNewswire/ -- Curadh MTR Inc. ("Curadh") and Alpha Fusion, Inc. ("Alpha Fusion") will present on the clinical development of radiopharmaceutical products at the ...